Brivanib alaninate for cancer

Bibliography

• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;20:401-10
   Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803
   PubMed Web of Science ®Google Scholar
• Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-43
   PubMed Web of Science ®Google Scholar
• Posey JA, Ng TC, Yang B, A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9:1323-32
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7
   PubMed Web of Science ®Google Scholar
• Tang JR, Markham NE, Lin YJ, Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287:L344-51
   PubMed Web of Science ®Google Scholar
• Izzedine H, Rixe O, Billemont B, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50:203-18
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 2005;8:269-71
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29
   PubMed Web of Science ®Google Scholar
• Cappellen D, De Oliveira C, Ricol D, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20
   PubMed Web of Science ®Google Scholar
• Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008;4:71-83
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-17
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085-94
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Bhide RS, Cai ZW, Zhang YZ, Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006;49:2143-6
   PubMed Web of Science ®Google Scholar
• Cai ZW, Zhang Y, Borzilleri RM, Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008;51:1976-80
   PubMed Web of Science ®Google Scholar
• Fargnoli J, Bhide R, Lombardo L, Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases [abstract 3033]. AACR Meeting Abstracts 2005
   Google Scholar
• Shiang CY, Qi Y, Wang B, Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 2010;123:747-55
   PubMed Web of Science ®Google Scholar
• Bhide RS, Lombardo LJ, Hunt JT, The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010;9:369-78
   PubMed Web of Science ®Google Scholar
• Ayers M, Dito G, Henley B, Comparison of a dual inhibitor of VEGF and FGF signaling, BMS-582664, to the activity of bevacizumab, an inhibitor exclusively of VEGF signaling, in xenograft models of colon carcinoma [abstract 1618]. AACR Meeting Abstracts 2007
   Google Scholar
• Poon RT, Ng IO, Lau C, Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001;182:298-304
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Fargnoli J, Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-53
   PubMed Web of Science ®Google Scholar
• Rosen LS, Wilding G, Sweeney C, Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol 2006;24: abstract 3051
   Web of Science ®Google Scholar
• Garrett CR, Siu LL, El-Khoueiry AB, A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J Clin Oncol 2008;26: abstract 4111
   PubMed Web of Science ®Google Scholar
• Investigator Brochure. Brivanib Alaninate/Brivanib (BMS-582664/BMS-540215). Version date: 27-April-2010
   Google Scholar
• Bristol-Myers Squibb. Ascending multiple-dose study of brivanib alaninate in combination with chemotherapeutic agents in subjects with advanced cancers. ClinicalTrials.gov NCT00798252. Available from: http://clinicaltrials.gov/ct2/show/NCT00798252?term=NCT00798252&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Lockhart AC, Rothenberg ML, Dupont J, Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14
   PubMed Web of Science ®Google Scholar
• Cheng HL. Dynamic contrast-enhanced MRI in oncology drug development. Curr Clin Pharmacol 2007;2:111-22
   PubMedGoogle Scholar
• Malone H, Pictroski C, Kukral D, Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) tumor microcirculation studies in tumor bearing mice treated with VEGFR inhibitor BMS-582664 [abstract 3869]. AACR Meeting Abstracts 2005
   Google Scholar
• Bueno-de-Mesquita JM, Linn SC, Keijzer R, Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009;117:483-95
   PubMed Web of Science ®Google Scholar
• Glinsky GV, Glinskii AB, Stephenson AJ, Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23
   PubMed Web of Science ®Google Scholar
• Glinsky GV. “Stemness” genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008;26:2846-53
   PubMed Web of Science ®Google Scholar
• Ayers M, Fargnoli J, Lewin A, Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007;67:6899-906
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Rosen LS, Sawyer M, A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol 2007;25: abstract 3559
   Web of Science ®Google Scholar
• Platero S, Mokliatchouk O, Jayson GC, Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases. J Clin Oncol 2008;26: abstract 3506
   Web of Science ®Google Scholar
• Marathe PH, Kamath AV, Zhang Y, Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 2009;65:55-66
   Google Scholar
• Hurwitz H, Lorusso P, Shapiro GI, Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors. Eur J Cancer 2008;6: abstract 429
   Web of Science ®Google Scholar
• Bristol-Myers Squibb. A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction. ClinicalTrials.gov NCT00437424. Available from: http://clinicaltrials.gov/ct2/show/NCT00437424?term=NCT00437424&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Nuyten DSA, Velasquez L, Garrett C, Response assessment by CT and [18F] FDG-PET in a phase I study of brivanib, an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab in patients with advanced gastrointestinal malignancies (AGM) [abstract 333]. Proceedings of the Gastrointestinal Cancers Symposium; 2009
   Google Scholar
• Ayers M, Awad M, Malone D, Correlation between K-ras status and efficacy results from a phase I/II study of brivanib alaninate in combination with cetuximab in patients (pts) with advanced or metastatic colorectal cancer (CRC) [abstract 375]. Proceedings of the Gastrointestinal Cancers Symposium; 2009
   Google Scholar
• Bristol-Myers Squibb. Phase I/II Combination With Irinotecan- Erbitux. ClinicalTrials.gov NCT00594984. Available from: http://clinicaltrials.gov/ct2/show/NCT00594984?term=NCT00594984&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Park YS, El-Khoueiry A, Cubillo A, A blinded placebo (P) controlled phaseI/II dose escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild type (KWT) advanced or metastatic colorectal cancer (AMCRC): Safety, tolerability and pharmacokinetic (PK) findings. Ann Oncol 2007;21(Suppl 8): abstract 614P
   Google Scholar
• Bristol-Myers Squibb. Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI). ClinicalTrials.gov NCT01046864. Available from: http://clinicaltrials.gov/ct2/show/NCT01046864?term=NCT01046864&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• NCIC Clinical Trials Group. Cetuximab With or Without Brivanib in Treating Patients With Metastatic Colorectal Cancer. ClinicalTrials.gov NCT00640471. Available from: http://clinicaltrials.gov/ct2/show/NCT00640471?term=NCT00640471&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Raoul JL, Finn RS, Kang YK, An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009;27: abstract 4577
   Google Scholar
• Finn RS, Raoul J-L, Manekas D, An analysis of brivanib phase 2 data to investigate optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC) [abstract 0-031]. International Liver Cancer Association Annual Conference; 2010
   Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. First Line Hepato Cellular Carcinoma (HCC) ClinicalTrials.gov NCT00858871. Available from: http://clinicaltrials.gov/ct2/show/NCT00858871?term=NCT00858871&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Bristol-Myers Squibb. Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment. ClinicalTrials.gov NCT00825955. Available from: http://clinicaltrials.gov/ct2/show/NCT00825955?term=NCT00825955&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Bristol-Myers Squibb. Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC. ClinicalTrials.gov NCT00908752. Available from: http://clinicaltrials.gov/ct2/show/NCT00908752?term=NCT00908752&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Bristol-Myers Squibb. Ascending multiple-dose study of brivanib alaninate in combination with chemotherapeutic agents in subjects with advanced cancers. ClinicalTrials.gov NCT00798252. Available from: http://clinicaltrials.gov/ct2/show/NCT00798252?term=NCT00798252&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Bristol-Myers Squibb. Phase II study of brivanib (BMS-582664) to treat multiple tumor types. ClinicalTrials.gov NCT00633789. Available from: http://clinicaltrials.gov/ct2/show/NCT00633789?term=NCT00633789&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Gynecologic Oncology Group. Brivanib alaninate in treating patients with recurrent or persistent endometrial cancer. ClinicalTrials.gov NCT00888173. Available from: http://clinicaltrials.gov/ct2/show/NCT00888173?term=NCT00888173&rank=1 [Last accessed 24 February 2011]
   Google Scholar
• Roodink I, Leenders WP. Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett 2010;299:1-10
   PubMed Web of Science ®Google Scholar